President and Managing Partner at BioPlan Associates, Inc. He is also the editor of Advances in Biopharmaceutical Technology in India.
Advances in techniques and single-use systems are revolutionizing vaccine manufacturing.
The industry may not be ready for India and China as regulatory issues emerge.
Outsourcing is weighing in more as a tactic for cost-cutting, but it is still not the primary weapon.
BioPlan's Annual Report shows continued growth in the use of single-use technology.
BioPlan's outsourcing survey gives insight on top activities, budgets, and growth trends in biopharmaceutical outsourcing.
Growth is seen in outsourcing of insect- and plant-cell-based bioproduction expression systems.
Will international biomanufacturing outsourcing become mainstream in this decade?
What the industry's future holds and what needs to be done to get there.
Budgets for biopharma activities are gaining in select functional areas, except outsourcing.